Different molecular mechanisms of vitamin D3 receptor antagonists

被引:55
作者
Toell, A
Gonzalez, MM
Ruf, D
Steinmeyer, A
Ishizuka, S
Carlberg, C
机构
[1] Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland
[2] Univ Dusseldorf, Inst Physiol Chem 1, D-4000 Dusseldorf, Germany
[3] Univ Dusseldorf, Biomed Forschungszentrum, D-4000 Dusseldorf, Germany
[4] Schering AG, Med Chem, D-1000 Berlin, Germany
[5] Teijin Inst Biomed Res, Dept Bone & Calcium Metab, Tokyo, Japan
关键词
D O I
10.1124/mol.59.6.1478
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two structurally different antagonists of the nuclear hormone 1 alpha ,25-dihydroxyvitamin D-3 [1 alpha ,25(OH)(2)D-3], the 25-carboxylic ester ZK159222 and the 26,23-lactone TEI-9647, have recently been described. In this study, the molecular mechanisms and the efficacy of both antagonists were compared. ZK159222 showed similar potency and sensitivity to 1 alpha ,25(OH)(2)D-3 in ligand-dependent gel shift assays using the vitamin D receptor (VDR), the retinoid X receptor, and specific DNA binding sites, whereas TEI-9647 displayed reduced potency and >10-fold lower sensitivity in this assay system. Limited protease digestion and gel shift clipping assays showed that the two antagonists stabilized individual patterns of VDR conformations. Both antagonists prevented the interaction of the VDR with coactivator proteins, as demonstrated by GST-pull-down and supershift assays; like the natural hormone, however, they were able to induce a dissociation of corepressor proteins. Interestingly, ZK159222 demonstrated functional antagonism in reporter gene assays both in HeLa and MCF-7 cells, whereas TEI-9647 functioned as a less sensitive antagonist only in MCF-7 cells. In conclusion, the two 1 alpha ,25(OH)(2)D-3 analogs act in part via different molecular mechanisms, which allows us to speculate that ZK159222 is a more complete antagonist and TEI-9647 a more selective antagonist.
引用
收藏
页码:1478 / 1485
页数:8
相关论文
共 28 条
[1]   Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains [J].
Bourguet, W ;
Vivat, V ;
Wurtz, JM ;
Chambon, P ;
Gronemeyer, H ;
Moras, D .
MOLECULAR CELL, 2000, 5 (02) :289-298
[2]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[3]  
Bula CM, 2000, MOL ENDOCRINOL, V14, P1788, DOI 10.1210/me.14.11.1788
[4]   2 NUCLEAR SIGNALING PATHWAYS FOR VITAMIN-D [J].
CARLBERG, C ;
BENDIK, I ;
WYSS, A ;
MEIER, E ;
STURZENBECKER, LJ ;
GRIPPO, JF ;
HUNZIKER, W .
NATURE, 1993, 361 (6413) :657-660
[5]   Gene regulation by vitamin D3 [J].
Carlberg, C ;
Polly, P .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (01) :19-42
[6]   The vitamin D-3 receptor in the context of the nuclear receptor superfamily - The central role of the retinoid X receptor [J].
Carlberg, C .
ENDOCRINE, 1996, 4 (02) :91-105
[7]   MECHANISMS OF NUCLEAR SIGNALING BY VITAMIN-D-3 - INTERPLAY WITH RETINOID AND THYROID-HORMONE SIGNALING [J].
CARLBERG, C .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 231 (03) :517-527
[8]   Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors [J].
Feng, WJ ;
Ribeiro, RCJ ;
Wagner, RL ;
Nguyen, H ;
Apriletti, JW ;
Fletterick, RJ ;
Baxter, JD ;
Kushner, PJ ;
West, BL .
SCIENCE, 1998, 280 (5370) :1747-1749
[9]   Recent developments in molecular action of antihormones [J].
Fuhrmann, U ;
Parczyk, K ;
Klotzbücher, M ;
Klocker, H ;
Cato, ACB .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (07) :512-524
[10]   DIFFERENTIAL RECOGNITION OF TARGET GENES BY NUCLEAR RECEPTOR MONOMERS, DIMERS, AND HETERODIMERS [J].
GLASS, CK .
ENDOCRINE REVIEWS, 1994, 15 (03) :391-407